Additionally, a phase 1 feasibility trial (NCT04750473) is employing Fluciclovine and PSMA as radiotracers in PET/CT imaging, aiming to detect and stage lobular variant breast cancer and evaluate concordance and discordance rates between the two imaging methods. Here, FOLH1 is linked to breast carcinoma.